Dollars for Profs
Dig Into University Researchers' Outside Income and Conflicts of Interest
Published Dec. 6, 2019
This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.
Conflict of Interest
Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.
Should you be removed from our database? Contact us at [email protected]. Read more below.
David Goldstein
Jackson Laboratory, Department: Na
Should you be removed from our database? Contact us at [email protected]. Read more below.
Columbia University
Equity Interest - Non-publicly traded entity ( e.g., stock, stock option, or other ownership interest)
Dr. Goldstein holds equity ((b)(4)) in Praxis Precision Therapeutics, a non-public company focused on epilepsy drug development (but whose compounds are not part of this PHS project). In light of these facts, Columbia found that Dr. Goldstein’s significant financial interest in Praxis Precision Therapeutics could affect the design, conduct, or reporting of the research.
The Jackson Laboratory Center for Precision Genetics: From New Models to Novel Therapeutics
Despite recent advances in biomedical technology and methods, the translation of discoveries to useful clinical therapies remains inefficient and difficult. Organisms that model disease, a vital part of the translational process, need to be made more precise and more relevant to human disease mechanisms. The pilot JAX Center for Precision Genetics (JCPG) is a multi-component Center that will provide diverse research teams with the support and infrastructure necessary to develop, characterize and refine mouse models for incurable and genetically complex human diseases. The JCPG pipelines developed in this pilot project will be applicable and responsive to new disease areas, models and technological advances in forthcoming years.
Filed on July 17, 2019.
Tell us what you know about David Goldstein's disclosure
We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?
Other search results for: “David Goldstein”
| Name | Institution | Type | Company | Disclosed Value |
|---|---|---|---|---|
| David Goldstein | Columbia University Health Sciences | Conflict of Interest | Pairnomix | Value cannot be readily determined |
| David Goldstein | Columbia University Health Sciences | Conflict of Interest | Praxis Precision Medicines | Value cannot be readily determined |
Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.
Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.
ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.